ELDN (Eledon Pharmaceuticals) OCF Yield %: -22.62 (As of Jul. 03, 2026)


ELDN Eledon Pharmaceuticals Inc ELDN
21 GF Score
Price $3.95
! 2 Warning Signs
View Full Analysis

What is Eledon Pharmaceuticals OCF Yield %?

Eledon Pharmaceuticals ELDN +1.28% 21 OCF Yield % is -22.62 as of Jul. 03, 2026. GuruFocus rates ELDN with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 1,414 Biotechnology companies, Eledon Pharmaceuticals ranks worse than 70.79% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Eledon Pharmaceuticals's Trailing 12-Month Cash Flow from Operations is $-68.89 Mil, and Market Cap is $304.51 Mil. Therefore, Eledon Pharmaceuticals's OCF Yield % for today is -22.62%.

The historical rank and industry rank for Eledon Pharmaceuticals's OCF Yield % or its related term are showing as below:

ELDN' s OCF Yield % Range Over the Past 10 Years
Min: -22.62   Med: 0   Max: -22.62
Current: -22.62

During the past 13 years, the highest OCF Yield % of Eledon Pharmaceuticals was -22.62%. The lowest was -22.62%. And the median was %.

ELDN's OCF Yield % is ranked worse than
70.79% of 1414 companies
in the Biotechnology industry
Industry Median: -8.155 vs ELDN: -22.62

Eledon Pharmaceuticals's OCF Margin % for the quarter that ended in Mar. 2026 was %.

Eledon Pharmaceuticals OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Eledon Pharmaceuticals OCF Yield % Related Terms

Eledon Pharmaceuticals OCF Yield % Historical Data

* Premium members only.

The historical data trend for Eledon Pharmaceuticals's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eledon Pharmaceuticals OCF Yield % Chart

Eledon Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -45.83 -90.49 -90.69 -19.19 -54.73

Eledon Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.65 -43.66 -37.34 -49.49 -38.72

ELDN vs ZNTL, GLSI, SABS: OCF Yield % Comparison

For the Biotechnology subindustry, Eledon Pharmaceuticals's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eledon Pharmaceuticals OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eledon Pharmaceuticals's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Eledon Pharmaceuticals's OCF Yield % falls into.


ELDN
21GF Score
Eledon Pharmaceuticals Inc ELDN
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eledon Pharmaceuticals OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Eledon Pharmaceuticals's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-62.341 / 113.8993
=-54.73%

Eledon Pharmaceuticals's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-22.612 * 4 / 233.62416
=-38.72%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -22.62 mean?
Eledon Pharmaceuticals (ELDN) has a OCF Yield % of -22.62 as of Jul. 03, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Eledon Pharmaceuticals and its competitors. According to the industry distribution chart, Eledon Pharmaceuticals ranks #1001 out of 1414 companies in the Biotechnology industry, placing it in the top 70.8%.
Is Eledon Pharmaceuticals' OCF Yield % too high?
Eledon Pharmaceuticals' current OCF Yield % is -22.62. Based on the distribution chart, Eledon Pharmaceuticals ranks #1001 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Eledon Pharmaceuticals has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Eledon Pharmaceuticals' OCF Yield % compare to ZNTL and GLSI?
According to the Biotechnology industry distribution chart, Eledon Pharmaceuticals ranks #1001 out of 1414 companies for OCF Yield %. This places Eledon Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Eledon Pharmaceuticals and its competitors. Eledon Pharmaceuticals's current OCF Yield % is -22.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eledon Pharmaceuticals stock overvalued right now?
Eledon Pharmaceuticals (ELDN) has a current OCF Yield % of -22.62. The current OCF Yield % is -22.62. Eledon Pharmaceuticals' overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Eledon Pharmaceuticals (ELDN), the current OCF Yield % is -22.62 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eledon Pharmaceuticals Business Description

Other Exchanges 2TK:Germany
Address 19800 MacArthur Boulevard, Suite 250, Irvine, CA, USA, 92612
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
21GF Score

Get the complete analysis for ELDN

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.95
Price